Leerink Partnrs Estimates Shattuck Labs FY2024 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Stock analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($1.42) for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday. They set an “outperform” rating and a $4.00 price target on the stock. Four analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Down 2.5 %

Shares of STTK stock opened at $1.16 on Thursday. The firm has a market cap of $55.38 million, a price-to-earnings ratio of -0.76 and a beta of 1.66. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76. The company’s 50 day moving average is $1.24 and its 200 day moving average is $1.59.

Hedge Funds Weigh In On Shattuck Labs

Several large investors have recently modified their holdings of the business. Prosight Management LP raised its position in Shattuck Labs by 15.1% in the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after purchasing an additional 873,409 shares during the period. Millennium Management LLC grew its stake in shares of Shattuck Labs by 37.0% in the fourth quarter. Millennium Management LLC now owns 201,214 shares of the company’s stock valued at $243,000 after buying an additional 54,322 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Shattuck Labs by 476.4% in the 4th quarter. Deutsche Bank AG now owns 116,868 shares of the company’s stock valued at $141,000 after buying an additional 96,594 shares during the period. Bank of America Corp DE lifted its stake in Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after acquiring an additional 107,491 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in Shattuck Labs during the 4th quarter valued at about $1,270,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.